Epidemiology and clinical classification of onychomycosis.
OBJECTIVE
To review recent data - what is new in the epidemiology of onychomycoses? To identify the most relevant diagnostic criteria for effective therapy.


METHODS
The preliminary results of the European Onychomycosis Observatory (EUROO) study were analysed. In this international study, physicians completed questionnaires concerning patient profile and the disease.


RESULTS
One of the most interesting novel findings was that sampling requests were often not made [only 3.4% of general physicians (GPs) and 39.6% of dermatologists]. This means that no information about causative agent(s) was available, hindering appropriate treatment choice. Furthermore, contrary to previous findings, 70.7% of participants did not practice sports. Lastly, these preliminary findings showed that treatment strategy depends largely on the type of treating physician, with GPs preferring monotherapy and dermatologists preferring combination therapy.


CONCLUSIONS
A consensus was reached that treatment strategy should depend on the severity of nail involvement and the causative fungus. It is thus important to promote the importance of sampling. To simplify the choice of an appropriate treatment, onychomycosis may be divided into just two clinical groups: onychomycosis with and without nail matrix area involvement. However, the distinct clinical findings (number and type of affected nails, multimorbidity, drug interaction, etc.) in each individual case must be taken into account to ensure an appropriate treatment decision.
Effendy
I
I
Hautklinik, Klinikum Rosenhöhe, Städtische Kliniken Bielefeld, An der Rosenhöhe 27, Bielefeld, Germany.
Lecha
M
M
Feuilhade de Chauvin
M
M
Di Chiacchio
N
N
Baran
R
R
D000935:Antifungal Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015994:Incidence; D007391:International Cooperation; D008297:Male; D014009:Onychomycosis / Q000145:classification* / Q000188:drug therapy / Q000453:epidemiology*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000935:Antifungal Agents